Cost-effectiveness analysis of tislelizumab plus chemotherapy as first-line treatment for HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinoma
From the perspective of the Chinese healthcare system, TLE-CHM is not a cost-effective first-line treatment for advanced G/GEJ adenocarcinoma compared to chemotherapy.
Authors
- Cuihua Yuan
- Yufan Huang (ORCID: https://orcid.org/0000-0002-7186-4071)
- Guangwu Guo (ORCID: https://orcid.org/0009-0008-7594-124X)
- Liangliang Zou
Institutions
- Fujian Medical University (CN)
- Second Military Medical University (CN)
- Eastern Hepatobiliary Surgery Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-05-22
- DOI
- https://doi.org/10.3389/fphar.2025.1500729
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Fujian Province